Sort
130,381 grants matching “hiv”
Center for Novel Therapeutics for HIV-Associated Cognitive Disorders
$808,353Justin C McArthur · Johns Hopkins University · P30 · FY2016 · MH
HIGH RISK DRUG USE &HIV--LEARNING FROM THE NYC EPIDEMIC
$808,350National Development &Res Institutes · P30 · FY2002 · DA
Regulation Of Immunopathology In Bacterial And Parasitic Disease
$808,335Alan Sher · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
B-cell biology scientific research support component
$808,334Garnett H Kelsoe · Duke University · UM1 · FY2014 · AI
Engraftment and in vivo selection of HIV-protected stem cells
$808,300Hans-Peter Kiem · Fred Hutchinson Cancer Research Center · R01 · FY2016 · HL
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIV
$808,293Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · AI
Portable Transdermal Acoustic Patch for Delivery of Large Molecules to Improve HIV Patient Medication Regime Compliance by Elimination of Side-Effects, Including Injection Site Reactions
$808,204Maureen L. Mulvihill · Actuated Medical, Inc. · R44 · FY2016 · AI
Evaluating the Link between HIV Prevention and Treatment
$808,180A. David Paltiel · Yale University · R01 · FY2008 · MH
HIV-Receptor Interactions and Related Anti-HIV Strategies
$808,155Edward Berger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
SAMIPS-NPC: Southern Africa Mother Infant Pertussis Study, Nasopharyngeal Carriage
$808,130Christopher J Gill · Boston University Medical Campus · R01 · FY2017 · AI
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV
$808,120Michael J Silverberg · Kaiser Foundation Research Institute · R01 · FY2024 · CA
HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
$808,117University Of California Los Angeles · R01 · FY2005 · DA
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
$808,114Takara Leah Stanley · Massachusetts General Hospital · R01 · FY2019 · DK
Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure
$808,087Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2022 · AI
Video DOT and Economic Incentives to promote adherence to LTBI therapy
$808,064Maunank Shah · Johns Hopkins University · R01 · FY2024 · AI
SIV Pathogenesis in African Green Monkeys and Pigtailed Macaques
$808,058Ivona Pandrea · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · HL
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV
$808,055Michael J Silverberg · Kaiser Foundation Research Institute · R01 · FY2022 · CA
Effect of Mindfulness Training on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment
$808,010Zev David Schuman Olivier · Cambridge Health Alliance · R33 · FY2020 · AT
Regulation of HIV latency by microglial-neuronal interactions
$807,952Jonathan Karn · Case Western Reserve University · R01 · FY2019 · DA
Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing in Community Health Centers (PrEDICT)
$807,908Julia L. Marcus · Harvard Pilgrim Health Care, Inc. · R01 · FY2023 · MH
Deciphering Mechanisms of HIV Latency Reversal in Perinatal Infections
$807,906Deborah Persaud · Johns Hopkins University · R01 · FY2020 · AI
NATURAL HISTORY OF MENOPAUSE IN HIV INFECTED DRUG USERS
$807,905Montefiore Medical Center (Bronx, Ny) · R01 · FY2004 · DA
Intervention to Enhance PrepPersistence Among African American Men Who Have Sex With Men
$807,777Amy Stewart Nunn · Brown University · R01 · FY2023 · MH
Structural Racism and Discrimination in Older Men's Health Inequities
$807,774Jesus Ramirez-Valles · University Of California, San Francisco · R01 · FY2023 · AG
HERPESVIRUS-ASSOCIATED MALIGNANCIES IN HIV PATIENTS
$807,762Johns Hopkins University · P01 · FY2002 · CA